# US 6,730,662 B1 · Adenovirus E4 proteins for inducing cell death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,662 B1
- Document ID: US6730662B1
- Status: Granted
- Kind: B1
- Application number: 09/214,478
- Filed: 1999-06-07
- Granted: 2004-05-04
- Earliest claimed: 1996-07-05
- Assignees: McGill University
- Inventors: Philip E. Branton; Gordon C. Shore; Jose G. Teodoro; Richard C. Marcelius; Josee N. Lavoie
- Web page: https://patentgrep.com/patent/US6730662B1

## CPC

- C07K 14/005: from viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention features E4orf4-encoding nucleic acids, pharmaceutical compositions and expression vectors containing the same, and methods for their use. E4orf4-encoding nucleic acids include (i) nucleic acids capable of hybridizing at high stringency to the complement of the nucleic acid encoding Ad2E4orf4, and (ii) nucleic acids having 50% or greater nucleotide sequence identity to the nucleotide sequence of Ad2E4orf4, so long as the nucleic acids encode a polypeptide capable of inducing apoptosis.

## Claims

### Claim 1

A method inducing apoptosis of a cell, said method comprising (a) administering to said cell by intratumoral injection a nucleic acid encoding a polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, said nucleic acid operably linked to a heterologous regulatory sequence for expression of said polypeptide, and (b) expressing said nucleic acid in said cell, wherein expressing said nucleic acid in said cell induces apoptosis of said cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

### Claim 3 (depends on 1)

The method of claim 1, wherein said nucleic acid is in an adenoviral vector or a retroviral vector.

### Claim 4 (depends on 1)

The method of claim 1, wherein said cell is a cancer cell.

### Claim 5

A pharmaceutical composition comprising (i) an expression vector comprising a nucleic acid encoding an E4orf4 polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, and (ii) a pharmaceutically acceptable carrier, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said E4orf4 polypeptide in a mammalian cell, and wherein E4 polypeptides other than said E4orf4 polypeptide are not expressed by said vector.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

### Claim 7 (depends on 5)

The composition of claim 5, wherein said nucleic acid is in an adenoviral vector or a retroviral vector.

### Claim 8

An expression vector comprising a nucleic acid encoding an E4orf4 polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said E4orf4 polypeptide in a mammalian cell, and wherein E4 polypeptides other than said E4orf4 polypeptide are not expressed by said vector.

### Claim 9 (depends on 8)

The expression vector of claim 8, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

### Claim 10 (depends on 8)

The expression vector of claim 8, wherein said expression vector is an adenovirol vector or a retroviral vector.
